AVI Starts Duchenne Trial

Bothell, WA-based AVI Biopharma (NASDAQ: AVII) said today it has started dosing patients in a mid-stage trial of eteplirsen, an experimental RNA-based therapy for Duchenne Muscular Dystrophy. The study is expected to enroll 12 patients at Nationwide Children’s Hospital in Columbus, OH. Patients will get once-weekly intravenous infusions of the new drug, or a placebo, for 24 weeks, AVI said.

Trending on Xconomy